Calcifediol

SKU: orb1300775

Description

Calcifediol

Research Area

Metabolism Research

Key Properties

• CAS Number: 19356-17-3
• MW: 400.64
• Purity: 99.38%
• Formula: C₂₇H₄₄O₂
• SMILES: [H][C@@]12CC[C@H]([C@H](C)CCCC(C)(C)O)[C@@]1(C)CCC\C2=C/C=C1/C[C@H](O)CCC1=C
• Target: Endogenous Metabolite
• Solubility: Ethanol:16 mg/mL (39.94 mM);DMSO:100 mg/mL (249.6 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (9.98 mM);H2O:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• Target IC50:
  PTH:2 nM(ED50)|Vitamin D3:3.9 μM(ki)
• In Vivo:
  METHODS: Calcifediol (25 µg/kg) was administered dietary to rats for four weeks to study its role in pregnancy. Results: Calcifediol provided better vitamin D availability to the Other and fetus when administered during pregnancy compared to vitamin D3. No adverse effects on pregnancy outcome were observed, and further studies are needed to investigat the effects of Calcifediol on fetal brain VDR and GAD67 expression.
• In Vitro:
  Calcifediol, whether in liposomes or ethanolic solution, does not affec the release o the proinflammatory cytokine KC from Pseudomonas-infected murine epithelial cells. however, treating infected human bronchial 16 hBE cells with Calcifediol liposomes significantly reduces bacterial survival.

Storage & Handling

• Storage: keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

RO 8-8892, VD/VDR, Vitamin, Vitamin D, Vitamin D receptor, U 32070E, inhibit, Inhibitor, EndogenousMetabolite, Endogenous Metabolite, 25-hydroxy Vitamin D3, Calcifediol

Compound Identifiers

PubChem CID

9952843